Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) and Vaxcyte (NASDAQ:PCVX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.
Valuation and Earnings
This table compares Aligos Therapeutics and Vaxcyte”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aligos Therapeutics | $7.97 million | 141.08 | -$87.68 million | ($1.28) | -11.24 |
| Vaxcyte | N/A | N/A | -$402.27 million | ($4.28) | -27.28 |
Aligos Therapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aligos Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Vaxcyte | 0 | 0 | 7 | 0 | 3.00 |
Aligos Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 421.20%. Vaxcyte has a consensus target price of $147.50, indicating a potential upside of 26.34%. Given Aligos Therapeutics’ higher probable upside, equities research analysts plainly believe Aligos Therapeutics is more favorable than Vaxcyte.
Insider & Institutional Ownership
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility & Risk
Aligos Therapeutics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Profitability
This table compares Aligos Therapeutics and Vaxcyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aligos Therapeutics | -1,100.48% | -110.59% | -63.90% |
| Vaxcyte | N/A | -30.07% | -28.08% |
Summary
Aligos Therapeutics beats Vaxcyte on 7 of the 12 factors compared between the two stocks.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
About Vaxcyte
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
